Annamycin clinical trials
How each study uses annamycin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the annamycin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2018 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 2
Moleculin Biotech, Inc. (5) · Callisto Pharmaceuticals (2) · NYU Langone Health (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses annamycin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AMLRecruitingPhase 2/3Moleculin Biotech, Inc.NCT06788756Written as Liposomal Annamycin Injection in combination with Cytarabine Injection
- Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary MetastasesRecruitingPhase 1/2Maria Sklodowska-Curie National Research Institute of OncologyNCT05518526Written as Liposomal Annamycin (L-Annamycin)
- Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)CompletedPhase 1/2Moleculin Biotech, Inc.NCT05319587Written as Liposomal Annamycin
- Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary MetastasesCompletedPhase 1/2Moleculin Biotech, Inc.NCT04887298Written as Liposomal Annamycin (L-Annamycin)
- Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)CompletedPhase 1/2Moleculin Biotech, Inc.NCT03388749Written as Liposomal Annamycin
- Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)CompletedPhase 1/2Moleculin Biotech, Inc.NCT03315039Written as Liposomal Annamycin
- Chemotherapy in Treating Patients With Breast CancerCompletedPhase 1/2NYU Langone HealthNCT00012129Written as liposomal annamycin
- Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AMLTerminatedPhase 1Callisto PharmaceuticalsNCT00430443Written as Liposomal Annamycin
- Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic LeukemiaStatus unknownPhase 1/2Callisto PharmaceuticalsNCT00271063Written as Liposomal Annamycin
Codes
What other systems call annamycin · ClinicalTrials.gg INT003717
- MeSH (NLM) C080315annamycinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) SNU299M83QNAXTARUBICINConfirmed FDA, NLM, Wikidata
- Wikidata Q4767903annamycinConfirmed FDA, NLM, Wikidata
- DrugBank DB06420One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C080315 | annamycin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | SNU299M83Q | NAXTARUBICIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4767903 | annamycin | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB06420 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.